Form 4 for STLN Starling Oncology, Inc.
Accepted 2022-12-20 00:00:00 ET · period of report 2022-12-16 · accession 0001799191-22-000058 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-20 | 2022-12-16 | STLN | Miller Matthew P | COO | P - Purchase | $0.95 | +73.7K | 175.3K | +72% | +$70.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-16 | P | A | 73,684 | $0.95 | 175,325 | D | — | — | (F1) The purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 577 shares, with the reporting persons sale of shares of common stock on November 15, 2022. The reporting person has paid to the Issuer the full amount of the profit realized in connection with the short-swing transaction, less transaction costs, calculated in accordance with Section 16(b). |